Pfizer Inc. $PFE Shares Bought by Generali Investments Management Co LLC

Generali Investments Management Co LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 37.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 77,592 shares of the biopharmaceutical company’s stock after buying an additional 21,173 shares during the quarter. Generali Investments Management Co LLC’s holdings in Pfizer were worth $1,977,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of PFE. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its holdings in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Waterfront Wealth Inc. increased its position in shares of Pfizer by 43.3% during the second quarter. Waterfront Wealth Inc. now owns 18,487 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 5,588 shares in the last quarter. Finally, Flagship Harbor Advisors LLC lifted its holdings in Pfizer by 11.5% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 74,068 shares of the biopharmaceutical company’s stock valued at $1,795,000 after purchasing an additional 7,668 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to Pfizer’s BRAFTOVI regimen for metastatic colorectal cancer — expands label to first‑line use, supporting upside to oncology sales and the “bull case” narratives for PFE. Pfizer’s Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment
• Positive Sentiment: Analyses argue the BRAFTOVI approval could re‑shape Pfizer’s growth outlook in oncology, providing a clear revenue catalyst if uptake in first‑line mCRC is strong. The Bull Case For Pfizer (PFE) Could Change Following New First-Line BRAFTOVI Colorectal Cancer Approval
• Positive Sentiment: Pfizer secures rights to a new GLP‑1 candidate as the company broadens its obesity pipeline — a strategic move to chase a large market and diversify future revenue streams. Pfizer secures rights to new GLP-1 as obesity push gathers pace
• Neutral Sentiment: Dividend narrative remains supportive: articles highlighting Pfizer’s 6%+ yield and retiree flows into dividend funds underscore investor appetite for PFE income, which can stabilize the stock. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.
• Neutral Sentiment: Zacks upgraded Pfizer from “strong sell” to “hold,” a modest positive signal but not a bullish re‑rating; it may temper short‑term selling. Zacks.com
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of an “insurmountable” $15B–$20B revenue decline through 2030 — a bearish structural thesis that could cap valuation upside. RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study — a pipeline setback that reduces optionality in immunology and may modestly pressure sentiment. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PFE shares. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research note on Thursday, February 12th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Finally, Scotiabank started coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $27.70.

Pfizer Price Performance

Shares of PFE opened at $27.11 on Friday. The firm has a 50-day simple moving average of $26.08 and a two-hundred day simple moving average of $25.39. The stock has a market cap of $154.14 billion, a PE ratio of 19.93 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the company posted $0.63 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.